Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12943490 | 0.90 | — | — | |
| SCHEMBL932143 | 0.89 | — | — | |
| Lithium Ion SCHEMBL931760 | 0.88 | KDM4E (0.44) | KDM4EALDH1A1MAPT | |
| SCHEMBL943980 | 0.87 | — | — | |
| SCHEMBL942679 | 0.86 | ALDH1A1 (0.43) | KDM4EALDH1A1MAPT | |
| SCHEMBL12943554 | 0.83 | HTR1A (0.44) | — | |
| SCHEMBL27781919 | 0.78 | ALDH1A1 (0.53) | KDM4EALDH1A1MAPT | |
| SCHEMBL931445 | 0.77 | — | — | |
| SCHEMBL932393 | 0.76 | NOTUM (0.43) | KDM4EALDH1A1MAPT | |
| SCHEMBL931468 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859534-B2 | 2-carboxamide-7-piperazinyl-benzofuran derivatives | Acturum Life Science AB (SE) | 2014-10-14 | — | — | US | claimed |
| US-20130296296-A1 | 2-Carboxamide-7-Piperazinyl-Benzofuran Derivatives | Acturum Life Science AB (SE) | 2013-11-07 | — | — | US | claimed |
| EP-2448934-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | AstraZeneca AB (SE) | 2012-05-09 | — | — | EP | claimed |
| WO-2011002405-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | claimed |
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| US-8859534-B2 | 2-carboxamide-7-piperazinyl-benzofuran derivatives | Acturum Life Science AB (SE) | 2014-10-14 | — | — | US | disclosed |
| US-8859534-B2 | 2-carboxamide-7-piperazinyl-benzofuran derivatives | Acturum Life Science AB (SE) | 2014-10-14 | — | — | US | disclosed |
| US-8859534-B2 | 2-carboxamide-7-piperazinyl-benzofuran derivatives | Acturum Life Science AB (SE) | 2014-10-14 | — | — | US | disclosed |
| EP-2448934-B1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES | ASTRAZENECA AB (SE) | 2014-05-21 | — | — | EP | disclosed |
| US-20130296296-A1 | 2-Carboxamide-7-Piperazinyl-Benzofuran Derivatives | Acturum Life Science AB (SE) | 2013-11-07 | — | — | US | disclosed |
| US-20130296296-A1 | 2-Carboxamide-7-Piperazinyl-Benzofuran Derivatives | Acturum Life Science AB (SE) | 2013-11-07 | — | — | US | disclosed |
| US-20130296296-A1 | 2-Carboxamide-7-Piperazinyl-Benzofuran Derivatives | Acturum Life Science AB (SE) | 2013-11-07 | — | — | US | disclosed |
| US-8367676-B2 | 2-carboxamide-7-piperazinyl-benzofuran derivatives 774 | ASTRAZENECA AB (SE) | 2013-02-05 | — | — | US | disclosed |
| US-8367676-B2 | 2-carboxamide-7-piperazinyl-benzofuran derivatives 774 | ASTRAZENECA AB (SE) | 2013-02-05 | — | — | US | disclosed |
| US-8367676-B2 | 2-carboxamide-7-piperazinyl-benzofuran derivatives 774 | ASTRAZENECA AB (SE) | 2013-02-05 | — | — | US | disclosed |
| EP-2448934-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | AstraZeneca AB (SE) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011002405-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | WO | disclosed |
| US-20100331341-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| US-20100331341-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| US-20100331341-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331341-A1 | 2-CARBOXAMIDE-7-PIPERAZINYL-BENZOFURAN DERIVATIVES 774 | C1R, HTR4, HTR2C | KDM4E 789/4885ALDH1A1 931/4885MAPT 836/4885 |
| US-20130296296-A1 | 2-Carboxamide-7-Piperazinyl-Benzofuran Derivatives | C1R, CBR1, HTR2C | KDM4E 1702/4885ALDH1A1 888/4885MAPT 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.